BioSpace News Archive

Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today the U.S. Food and Drug Administration (FDA) has broadened the Emergency Use Authorization (EUA) for baricitinib to allow for treatment with or without remdesivir, whereas the EUA was previously restricted to use only in combination with remdesivir.

BERG announced the publication of a new study, entitled “Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia” in Scientific Reports.

Like any other cancer, the treatment for blood cancer needs to be personalized to each patient.

A prosthetics implant is a device that substitutes the missing part of the body artificially that may have been lost due to congenital disorder, disease, or trauma.

Rise in prevalence of chronic diseases and behavioral health, increase in responsiveness toward stress management, and surge in awareness regarding mental disorders through education and advocacy for human rights fuel the growth of the global mental health market.

Cassava Sciences, Inc. (Nasdaq: SAVA) announced positive clinical data today from an interim analysis of an open-label study with simufilam, the Company’s investigational drug for the treatment of Alzheimer’s disease.

Cassava Sciences, Inc. (Nasdaq: SAVA) today announced positive biomarker data from an open-label study of simufilam, the Company’s investigational drug for the treatment of Alzheimer’s disease.

Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the publication of data from its Phase 1b OVATION 1 Study with GEN-1 in combination with neoadjuvant chemotherapy (NACT) in patients with advanced ovarian cancer in Clinical Cancer Research, a journal of the American Association for Cancer Research.

The U.S. Food and Drug Administration (FDA) has cleared for clinical lab use a gene sequencing test designed by molecular pathologists at NYU Langone Health and its Laura and Isaac Perlmutter Cancer Center to guide treatment decisions for patients that have received a cancer diagnosis.

The second part of the panel discussion will feature the clinical study and clinical data of the first 28 patients treated with ANVS401 in the Company’s ongoing Phase 2a trials.